---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-269359"
form_type: "8-K/A"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2023-11-02T23:59:59+00:00"
generated_at: "2026-06-09T00:42:39.873161+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mirum acquires Bile Acid Business from Travere for up to $445M; H1 2023 revenue $53.6M, net income $13.6M

## Summary
- Acquired Chenodal and Cholbam assets for up to $445M ($210M upfront + up to $235M milestone payments).
- PIPE of 8M shares at $26.25 raised ~$202.2M net proceeds to fund acquisition.
- Acquired business had net product sales of $53.6M and net income of $13.6M for H1 2023 (unaudited).
- Pro forma combined financial statements filed; acquisition closed August 31, 2023.

## SEC filing metadata
- accession: 0001193125-23-269359
- form_type: 8-K/A
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2023-11-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312523269359/0001193125-23-269359-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312523269359/d323300d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-269359
- JSON: https://secwatch.observer/filing/0001193125-23-269359.json
- Plain text: https://secwatch.observer/filing/0001193125-23-269359.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.